3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
127
Colonic Neoplasms
71
Rectal Neoplasms
56
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Stomach Neoplasms
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia
11
Carcinoma, Hepatocellular
11
Neoplasms
10
Lymphoma
10
Burkitt Lymphoma
8
Adenocarcinoma Of Esophagus
8
Cholangiocarcinoma
6
Adenocarcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Esophageal Neoplasms
5
Leukemia, Biphenotypic, Acute
4
Intestinal Neoplasms
4
Gastrointestinal Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Digestive System Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Gallbladder Neoplasms
3
Biliary Tract Neoplasms
3
Rectal Diseases
2
Neurotoxicity Syndromes
2
Interventions
aflibercept
3
Irinotecan
2
Bevacizumab
2
XELOX
1
Vemurafenib
1
Panitumumab
1
Leucovorin
1
IFL protocol
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Colorectal Cancer Metastatic
×
Leucovorin
×
Clear all
NCT01670721
2016-11-28
AFEQT
Sanofi
Phase 3
Completed
175 enrolled
6 charts